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Background: Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor which raises high-density lipoprotein
(HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol level, has been documented to increase
mortality and cardiac events associated with adverse effects. However, it is still unclear the underlying mechanisms
of the off-target effects of torcetrapib.
Results: In the present study, we developed a systems biology approach by combining a human reassembled
signaling network with the publicly available microarray gene expression data to provide unique insights into the
off-target adverse effects for torcetrapib. Cytoscape with three plugins including BisoGenet, NetworkAnalyzer and
ClusterONE was utilized to establish a context-specific drug-gene interaction network. The DAVID functional
annotation tool was applied for gene ontology (GO) analysis, while pathway enrichment analysis was clustered by
ToppFun. Furthermore, potential off-targets of torcetrapib were predicted by a reverse docking approach. In
general, 10503 nodes were retrieved from the integrative signaling network and 47660 inter-connected relations
were obtained from the BisoGenet plugin. In addition, 388 significantly up-regulated genes were detected by
Significance Analysis of Microarray (SAM) in adrenal carcinoma cells treated with torcetrapib. After constructing the
human signaling network, the over-expressed microarray genes were mapped to illustrate the context-specific
network. Subsequently, three conspicuous gene regulatory networks (GRNs) modules were unearthed, which
contributed to the off-target effects of torcetrapib. GO analysis reflected dramatically over-represented biological
processes associated with torcetrapib including activation of cell death, apoptosis and regulation of RNA metabolic
process. Enriched signaling pathways uncovered that IL-2 Receptor Beta Chain in T cell Activation, Platelet-Derived
Growth Factor Receptor (PDGFR) beta signaling pathway, IL2-mediated signaling events, ErbB signaling pathway
and signaling events mediated by Hepatocyte Growth Factor Receptor (HGFR, c-Met) might play decisive characters
in the adverse cardiovascular effects associated with torcetrapib. Finally, a reverse docking algorithm in silico
between torcetrapib and transmembrane receptors was conducted to identify the potential off-targets. This
screening was carried out based on the enriched signaling network analysis.
Conclusions: Our study provided unique insights into the biological processes of torcetrapib-associated off-target
adverse effects in a systems biology visual angle. In particular, we highlighted the importance of PDGFR, HGFR, IL-2
Receptor and ErbB1tyrosine kinase might be direct off-targets, which were highly related to the unfavorable
adverse effects of torcetrapib and worthy of further experimental validation.* Correspondence: xjli@bjmu.edu.cn
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Cardiovascular disease remains to be the most unexcep-
tional cause of morbidity over the past few years in spite
of the usage of hydroxymethylglutaryl coenzyme A
(HMG CoA) reductase inhibitors (statins) that lower
low-density lipoprotein (LDL) cholesterol [1]. Elevated
LDL or lowered high-density lipoprotein (HDL) choles-
terol level is a crucial risk factor for cardiovascular ail-
ments [2,3]. Accordingly, raising HDL induced by
cholesteryl ester transfer protein (CETP) inhibition is an
attractive tactic for anti-atherosclerosis, which may re-
duce the residual risk of cardiovascular events [4].
Torcetrapib (Figure 1), a CETP inhibitor firstly pro-
posed by Pfizer Inc., had been characterized to suppress
the exchange of HDL and triglyceride-rich lipoprotein in
patients with hyperlipidemia, which resulted in the ele-
vation of HDL in the peripheral circulatory system [5].
However, torcetrapib was found to be associated with in-
cremental mortality and cardiovascular event risk, in-
cluding activated aldosterone system and induced
hypertension in the ILLUMINATE trial [6]. Off-target
effects occurred via inhibition of a kinase not intendedFigure 1 Chemical structure of torcetrapib. ChemSpider (http://
www.chemspider.com/) ID: 140123; Molecular Formula:
C26H25F9N2O4; Average mass: 600.473328 Da; Systematic name: Ethyl
(2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-
ethyl-6-(trifluoromethyl)-3,4-dihydro-1(2H)-quinolinecarboxylate.to be targets for drugs. So far, the detailed mechanisms
underlying the off-target adverse effects of torcetrapib
are quite limited and remain obscure.
With the rapid development of high-throughput
screen (HTS) technology such as microarray, the super-
iority of systems biology and network pharmacology
gradually embodied [7,8]. Reconstructing networks of
biological organism through integrating diverse sources
are crucial for comprehending biological processes asso-
ciated with pathema. Computational biology provides
profitable patronage to address the scientific suspense
through pragmatic modeling and theoretical exploration,
which furnish a brand-new network poly-pharmacology
approach for drug identification and discovery [9]. Based
on systems biology, it affords a rewarding assistance to
improve drug potency and forecast the unwanted off-
target effects at a higher efficiency and lower attrition,
especially for a new generation of known drugs [10]. In
addition, as a crucial technology in drug discovery, re-
verse docking approach also revealed a prominent per-
formance in understanding the basis of a drug and
receptors which provided benignant avails in drug target
identification [11].
To better expound the unfavorable adverse reactions
of torcetrapib, a novel network systems approach was
proposed by integrating high quality manually curated
data with microarray gene expression profiling into a
context-specific network, which allowed us to explicate
the off-target adverse effects of torcetrapib in a different
angle. Detailed illustrations are as follows.
Results and discussion
Although statins had been well characterized as the best
studied contemporary cardiovascular therapies over the
past few years, the optimal approach to LDL reduction
remained to be controversial. Meanwhile, the prejudice
of low levels of HDL cholesterol in cardiovascular sys-
tem became increasingly prominent, which had a tight
consanguinity with myocardial infarction and death from
coronary heart disease (CHD). Thus, strategies targeting
HDL had been a therapeutic tactic for anti-atheroscler-
osis. As a novel CETP inhibitor, torcetrapib had been
recognized as one of the auspicious foremost candidates
for elevating HDL. However, owing to its high risk of
mortality, torcetrapib experienced the battle of “Water-
loo”, which overshadowed the entire prospect of anti-
cholesterol drugs.
With the speedy development of bioinformatics,
organization of knowledge on drug, disease and target
inaugurated a brand-new era in drug target identification
and discovery. Network pharmacology comprehended
the complexity of biological processes by integrating net-
work biology and poly-pharmacological perspective to
create predictive models [12]. Network reconstruction
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could uncover the capital gene regulatory networks
(GRNs) modules which led to the dysfunction of regular
biological systems.
After integrating HPRD (Human Protein Reference
Database, http://www.hprd.org/) with a manually cu-
rated human signaling network acquired from Cui et al.
[13], the over-expressed microarray data originated from
human adrenal carcinoma cells treated with torcetrapib
were mapped to construct the context-specific network.
Cytoscape (http://www.cytoscape.org/), an open source
package for visualizing complex networks and integrat-
ing diverse types of resources, is an indispensable plat-
form for bioinformatics, social network analysis and
network pharmacology [14]. The drug-gene interaction
network of torcetrapib was established utilizing three
plugins, including BisoGenet [15], NetworkAnalyzer and
ClusterONE [16]. Molecular relations (protein-protein
and protein/DNA interactions) were connected based
on SysBiomics platform (http://biomine.cigb.edu.cu/
sysbiomics/). GRNs communities, which reflected the
situation of torcetrapib-associated over-expressed genes,
were detected in MCODE algorithm. The DAVIDFigure 2 SAM plot sheet output of the gene expression profiling of t
GDS3556). SAM plot sheet illustrated a signature for differentially expresse
dots represented gene sets up-regulated.functional annotation tool (http://david.abcc.ncifcrf.gov/)
[17,18] and ToppFun web server (http://toppgene.cchmc.
org/enrichment.jsp) [19] were employed freely to identify
the significantly-represented biological processes and the
enriched signaling pathways, respectively.
An in silico drug target reverse searching method
was applied for screening potential off-targets of torce-
trapib. Reverse docking, a flexible ligand-receptors in-
verse docking program, conducted computer-automated
search of potential targets of a small molecule by dock-
ing it to a cavity of each receptor. To optimize docking
parameter, an accurate docking module in Discovery
Studio (version 2.5, Accelrys) named CDOCKER was
employed. The cavity of each protein was derived from
the three dimensional structures of Protein Data Bank
(PDB, http://www.rcsb.org/) based on the enriched path-
ways. Proteins with high binding affinity with torcetrapib
were considered to be the most potential direct off-
targets.
Torcetrapib-associated signaling map construction
Totally, 388 differentially expressed genes were identified
by SAM (Additional file 1). As shown in Figure 2, withhe microarray dataset from a study of torcetrapib (GEO:
d genes of H295 adrenal carcinoma cells treated with torcetrapib. Red
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of two parallel lines with a distance of 1.1724 (delta
value) according to the False Discovery Rate (FDR)
threshold of 0.05. After combining HPRD (Raw data is
available in Additional file 2) with a manually curated
human signaling network obtained from Cui et al. [13],
an integrated human signaling network contained 10503
nodes and 47660 edges were connected on the basis of
SysBiomics platform, which amassed miscellaneous data
from BIND, HPRD, MINT, DPI, BIOGRID and INTACT
[15]. To uncover torcetrapib-associated regulatory net-
work, 215 out of the 388 significantly up-regulated genes
were mapped to illustrate the context-specific network.GRNs modules excavation
Genes in biological networks always enjoy a similarity in
which they are more intimately connected to implement
particular biological functions. This kind of dense
clique-like structure within a network theme is termed
as GRNs modules or gene sets [20]. GRNs, the specific
sub-networks that gave rise to the dysfunction of regula-
tor in biological systems, were critical in maintaining the
stability of the entire network. Thus, analysis of gene lists
regulated by the over-represented microarray genes was
propitious to annotate the specific biological processes
involved in torcetrapib-associated undesired off-target
effects. Currently, we utilized the MCODE algorithm in
ClusterONE plugin, which searched nodes for expansion
by computing a score of local density for each node in a
graph, to detect the dominant controller of gene regula-
tion associated with torcetrapib. Totally, the largest three
principal modules (Figure 3) encoded by torcetrapib-
gene expression profiling (with score above 2.0) were
excavated and the complete lists of the core GRNs were
presented in Additional file 3.Figure 3 Significant up-regulated torcetrapib signature driving genes
modules (circle layout). (A) For GRN1. (B) For GRN2. (C) For GRN3.Gene ontology (GO) analysis
To assess the capital GRNs in biological processes, the
DAVID functional annotation tool was utilized [17,18].
Our results for the enriched over-represented biological
processes implicated in torcetrapib were presented in
Figure 4 (FDR<0.01). Of note, most of these functions
were highly bound up with cell death, apoptosis, signal-
ing transduction, tyrosine modification and regulation of
RNA metabolic process.
Pathway enrichment analysis
Pathway, a set of genes that acted together to implement
certain biological functions, was an excellent indicator to
annotate dysregulation in view of gene regulation. Thus,
we speculated the regulated pathways of the momentous
gene sets based on ToppFun, a web server for compara-
tive enrichment analysis of multiple gene lists [19]. Sig-
nificant over-expressed pathways of the capital GRNs
were listed in Table 1 (FDR<0.05). Accordingly, torcetra-
pib mainly influenced IL-2 Receptor Beta Chain in T cell
Activation, Platelet-Derived Growth Factor Receptor
(PDGFR) beta signaling pathway, IL2-mediated signaling
events, ErbB signaling pathway and signaling events
mediated by Hepatocyte Growth Factor Receptor (HGFR,
c-Met) via up-regulation of CBL, SOCS1, JAK1, JUN,
TGFBR2 and EXOSC6.
Reverse docking analysis
Predicting potential binding receptors of ligands by
docking protocol could assist in new targets discovery
and identification. Reverse docking approach, the oppos-
ite of the direct docking method firstly proposed by
Chen et al. [11], could identify probable binding proteins
for a specific small molecule. CDOCKER, an accurate
docking module in Discovery Studio, is a powerful tool
to predict the conformation and related binding energies(central location) in the gene regulatory networks (GRNs)
Figure 4 Heatmap of the over-represented biological processes associated with torcetrapib generated by Cluster/TreeView. Columns
represented significant over-represented biological processes, while rows corresponded to gene regulatory networks (GRNs) modules. Expression
values were logarithm of ratio value utilizing log transform data. Red color in each grid represented positive, while white represented null.
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formance was conducted by docking torcetrapib to a
series of proteins based on the enriched signaling path-
ways. Our results for reverse docking targets of torcetra-
pib were listed in Table 2.
IL2-mediated signaling events and activation of T cell
receptor pathway mediated by IL-2 gave rise to the
unwanted effects for torcetrapib
Among the myriad of intra-cellular signaling networks
that governed the pathogenesis of cardiovascular event,
activation of T cell receptor signaling mediated by IL-2Table 1 Main enriched signaling pathways of torcetrapib rela
Index Driving genes Pathways
GRN1 CBL,SOCS1 BioCarta: IL-2 Receptor Beta Chain in T
CBL,SOCS1 NCI-Nature Curated: PDGFR-beta signal
SOCS1 NCI-Nature Curated: IL2-mediated signa
CBL KEGG pathway: ErbB signaling pathway
GRN2 JUN NCI-Nature Curated: Signaling events m
GRN3 EXOSC6 Reactome: Genes involved in mRNA De
EXOSC6 Reactome: Genes involved in Metabolis
EXOSC6 Reactome: Genes involved in Metabolis
FDR: false discovery rate.awoke our concern. Recently, numerous evidences illu-
strated that the pathological proceeding of atheroscler-
osis had an intimate relation with chronic inflammation
[21]. As a primary regulator of immune cell, the charac-
teristics of T cell receptor pathway mediated by IL-2 in
atherosclerosis had been certificated [22-25]. Lipid de-
position and infiltration of inflammatory cells were re-
sponsible for the formation of atherosclerosis and a
variety of cells such as T lymphocytes, monocytes,
macrophages, endothelial cells, platelet and vascular
smooth muscle cells were engaged in the occurrence






ediated by Hepatocyte Growth Factor Receptor (c-Met) 1.175E-4
cay by 3’ to 5’ Exoribonuclease 4.537E-14
m of mRNA 3.187E-8
m of RNA 6.834E-6
Table 2 Off-targets candidates for torcetrapib identified





1 PDGFR (1GQ5) crenolanib 28.7711
torcetrapib 42.0439
2 HGFR (3U6H) compound 03X 40.8298
torcetrapib 40.2422
3 IL-2 receptor (4HCV) compound 13 J 46.049
torcetrapib 38.126
4 ErbB1 (3BEL) compound POX 35.5674
torcetrapib 34.7466
Fan et al. BMC Systems Biology 2012, 6:152 Page 6 of 12
http://www.biomedcentral.com/1752-0509/6/152adhesion molecules and inflammatory chemokines were
other elements which facilitated the accumulation of
plaques. T cells activated by IL-2 in the arterial vessel
played a momentous function in atherosclerosis, which
induced apoptosis of vascular smooth muscle cells and
facilitated the formation of plaques [26].
Similarly, hypertension is also considered to be an in-
flammatory pathema [27,28]. Considerable documents
illustrated that T cells could stimulate the release of
cytokines and inflammatory factors, which resulted in
hypertension and myocardial fibrosis. As a vasoactive
peptide, angiotensin II (AngII) was identified as a crucialFigure 5 Prediction of IL-2 receptor as a possible off-target of torcetr
compound 13 J in the best docking pose. (B) Docked complex of IL-2 rece
torcetrapib were in the stick representation, whilst the amino acid residues
representation. C, H, O, N and F were colored with gray, white, red, blue anfactor in the development of hypertension. Activated T
cells mediated by IL-2 had been authenticated to be rich
in AngII receptor, which could promote the migration of
dendritic cells [29] and amplify inflammation through
autocrine [30,31]. More and more evidences attested the
relations between experimental hypertension and T cell
immune activation. Guzik et al. [32] found that mice
continuously infiltrated with AngII exhibited extraordin-
ary abnormalities of T cell. Further studies disclosed that
AngII significantly increased the amount of T cell in the
perivascular adipose tissue via enrichment of CD69/
CD44 or activation of Chemokines (C-C motif ) receptor
5, which subsequently elevated the level of T lympho-
cytes in the peripheral circulatory system. Thus, the off-
target prediction was applied by docking torcetrapib to
IL-2 receptor.
The X-ray crystallography of IL-2 receptor with an
endogenous ligand (compound 13 J, 3-{4-amino-1-
[(3S)-1-propanoylpiperidin-3-yl]-1H-pyrazolo[3,4-d]pyri-
midin-3-yl}-N-[4- (propan-2-yl)phenyl]benzamide) was
downloaded from PDB (PDB code 4HCV). Compound
13 J (Figure 5A), a nonreceptor tyrosine kinase Itk (inter-
leukin-2 inducible T- cell kinase) blocker, exhibited posi-
tive activities with IC50 0.4 μM. Figure 5 showed the
results of the calculations. The docking protocol revealed
that both compound 13 J and torcetrapib could cage intoapib. (A) Docked complex of IL-2 receptor (PDB code 4HCV) and
ptor and torcetrapib in the best docking pose. Compound 13 J and
of IL-2 receptor were displayed by solid ribbon style in the line
d brown, respectively.
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of torcetrapib and IL-2 receptor complex was de-
creased compared with compound 13 J (compound 13 J,
46.049 kcal/mol; torcetrapib, 38.126 kcal/mol). Docking
consequences elaborated that the conserves amino acid
residues LYS391, GLN373 and SER371 in IL-2 receptor
played a decisive role in maintaining the functional con-
formation and directly involved in compound 13 J and
torcetrapib binding.
PDGFR-beta signaling pathway and the adverse effects of
torcetrapib
Platelet derived growth factor (PDGF), a 24ku cationic
glycoprotein, mainly indwelt in platelet alpha granule,
impaired endothelial cell, macrophages, smooth muscle
cells, fibroblasts and mesangia cells, which mediated
multiple interactions between tissues and endothelial
cells through releasing PDGF in an autocrine and para-
crine chain amplificated reaction forms [33,34]. A variety
of mechanisms involved in the development of athero-
sclerosis had been reported to be highly associated with
PDGF. Cagnin et al. [35] discovered that a high level of
PDGF and interleukin was detected in patients with ath-
erosclerosis, suggesting that PDGF could influence
the proceeding of atherosclerosis in association with in-
flammatory factors. Additionally, Cha et al. [36] also
observed proliferation and migration in smooth muscle
cell after PDGF treatment in cultured human aortic
smooth muscle cells in vitro, which indicated that PDGF
could facilitate the formation of atherosclerosis via accel-
erating the migration and proliferation of plaque.
Despite the fact that percutaneous coronary interven-
tion (PCI) was one of the most effective therapeutic
approaches for CHD by far, restenosis after stenting was
still unavoidable, which affected the long term efficacy.
Li and colleagues [37] disclosed that the increased ex-
pression of PDGF mRNA was found on carotid artery
balloon dilatation rat. Experimental results suggested
that PDGF could activate its upstream pathways via dir-
ectly binding PDGFR-β, which initiated intermediate sig-
nal protein, activated mitogen activated protein kinase
pathway (MAPK) cascade afterwards and promoted pro-
liferation, migration and angiogenesis in smooth muscle
cells through dimerization and autophosphorylation of
tyrosine residues phosphorylated [38,39]. Chintalgattu’s
research [40] uncovered an elevation of PDGFR-β in car-
diac pressure overload mice, implicating that PDGFR-β
was a compensatory reaction in heart under pressure
load, which depicted the intimate relationship between
the activation of PDGFR signaling pathway and cardio-
vascular diseases.
Owing to the availability of synthetical PDGF tyrosine
kinase inhibitors, it might be conceivable to use crenola-
nib to exploit the binding pocket region of PDGFprotein. Figure 6 illustrated that torcetrapib perfectly
matched the crystallographic position of the PDGF
tyrosine kinase receptor (PDB Code 1GQ5) with
42.0439 kcal/mol by directly interacting with ARG40
and ARG80 in its besting docking pose. As is well
known, H-bonds play a vital role in the stability of struc-
ture and function of biological molecules. The presence
of interaction between ARG40 and ARG80 is interesting,
which had been identified as the most important amino
acid residue in the formation of hydrogen bond.
Aberrant ErbB pathway was associated with the off-target
effects for torcetrapib
Except for cancer, the ErbB family of four receptor tyro-
sine kinases (ErbB1, ErbB2, ErbB3 and ErbB4) also
engaged in certain non-neoplastic pathologies, such as
hypertension [41], infectious diseases [42] and chronic
renal dysfunction [43]. More recent studies have demon-
strated that neuregulins (NRGs)/ErbB1 signaling path-
way was essential for normal myocardial development
and pathological vasoconstriction, especially in cardiac
smooth muscle [44]. One such momentous NRGs was
heparin-binding (HB)-EGF. Hao et al. [41] reported that
the activation of ErbB1 receptor mediated by HB-EGF
played a significant role in cardio-vasculature and hyper-
tension, which facilitated the formation of atheroscler-
otic plaque and vascular stenosis.
The three dimensional structure of ErbB1 tyrosine kin-
ase with compound POX (4-amino-6-arylaminopyrimi-
dine-5-carbaldehyde oximes) was downloaded from PDB
(code number 3BEL). As shown in Figure 7, the binding
energy between torcetrapib and ErbB1 tyrosine kinase
experienced a lower reduction in the best docking pose
compared with compound POX (POX, 35.5674 kcal/mol;
torcetrapib, 34.7466 kcal/mol). Of note, the presence of
interaction in LYS913 aroused our curiosity, which was
proposed as the most prominent amino acid residue in
the stability of ErbB1 and POX/torcetrapib.
HGFR pathway contributed to the unfavorable effects of
torcetrapib
As a heparin binding glycoprotein originated from mes-
enchymal cells, hepatocyte growth factor (HGF) pos-
sessed various biological activities including regulating
mitosis, morphogenesis, hematopoiesis, myocardial
hypertrophy, angiogenesis, fibrosis and tissue regener-
ation, which were took effect via binding HGF specific
receptor kinase (c-Met) [45]. HGF promoted mitosis
and revealed anti-apoptosis effect on vascular endothe-
lial cells. Meanwhile, there was no stimulation of HGF
on the growth of smooth muscle cells, suggesting that it
was a specific endothelial cell growth factor and injury
repaired factor [46]. Previously, we found that HGF
played profitable prothetic roles in the pathogenesis of
Figure 6 Prediction of PDGFR as a possible off-target of torcetrapib. (A) Docked complex of PDGFR (PDB code 1GQ5) and crenolanib in the
best docking pose. (B) Docked complex of PDGFR and torcetrapib in the best docking pose. Crenolanib and torcetrapib were in the stick
representation, whilst the amino acid residues of PDGFR were displayed by solid ribbon style in the line representation. C, H, O, N and F were
colored with gray, white, red, blue and brown, respectively.
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paracrine mechanisms of HGF was reduced by high con-
centration of transforming growth factor β (TGF-β) and
AngII after endothelial damage in atherosclerosis, which
resulted in the elevation of serum HGF produced by
lung, liver and kidney to regulate the proliferation orFigure 7 Prediction of ErbB1 tyrosine kinase as a possible off-target o
compound POX in the best docking pose. (B) Docked complex of ErbB1 an
torcetrapib were in the stick representation, whilst the amino acid residues
line representation. C, H, O, N and F were colored with gray, white, red, blumigration of vascular endothelial and smooth muscle
cells [47,48].
The three dimensional crystal structure of HGF receptor
and compound 03X (N-{4-[(6,7-dimethoxyquinolin-4-yl)
oxy]-3-fluorophenyl}-1,5-dimethyl-3-oxo-2-phenyl-2,3-
dihydro-1H-pyrazole-4-carboxamide) showed that thef torcetrapib. (A) Docked complex of ErbB1 (PDB code 3BEL) and
d torcetrapib in the best docking pose. Compound POX and
of ErbB1 tyrosine kinase were displayed by solid ribbon style in the
e and brown, respectively.
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Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbox-
amide could interact with the hinge region of the active
site via directly coalescing with ARG1086 and ASN1171
(Figure 8). Similarly, a H-bond (ARG1166) adjacent to
the 6-(trifluoromethyl)-1, 2, 3, 4-tetrahydroquinoline ring
also contributed to the stability of torcetrapib and HGF
receptor.
As a CETP inhibitor, torcetrapib could activate rele-
vant signaling pathways mentioned above through dir-
ectly binding PDGFR, HGFR, IL-2 Receptor and
ErbB1tyrosine kinase and up-regulating CBL, SOCS1,
JAK1, JUN, TGFBR2 and EXOSC6 afterward, which sub-
sequently exerted the exacerbation of endothelium in-
jury and increased cardiovascular events [6]. Thus, a
synergetic combination of anti-hypertensive drugs such
as angiotensin converting enzyme inhibitors (ACEIs)
was proposed to be an effective and beneficial strategy
to decrease torcetrapib-associated off-target unfavorable
effects in cardiovascular system [49].
Conclusions
A whole genomic drug-gene interaction network based
on the integrative manually curated signaling network
and microarray profiles was established to explicate the
potential off-target effects for torcetrapib. Totally, three
momentous GRNs modules which might have a close re-
lationship with the unwanted effects of torcetrapib were
mined. Meanwhile, enriched analysis was carried out
and certain significant enriched pathways were detected,
which had been reported to have a definite correlationFigure 8 Prediction of HGFR as a possible off-target of torcetrapib. (A
the best docking pose. (B) Docked complex of HGFR and torcetrapib in the
representation, whilst the amino acid residues of HGFR were displayed by
colored with gray, white, red, blue and brown, respectively.with cardiovascular maladjustment. In particular, we
highlighted the importance of IL-2 Receptor Beta Chain
in T cell Activation, PDGFR-beta signaling pathway, IL2-
mediated signaling events, ErbB signaling pathway and
signaling events mediated by HGFR (c-Met) and
revealed that PDGFR, HGFR, IL-2 Receptor and ErbB1-
tyrosine kinase were direct off-targets for torcetrapib.
Taken together, these findings suggested that the net-
work off-target effects prediction methods in silico were
profitable for illustrating the relationship between drug
and disease related off-targets for interventions. How-
ever, due to the false positive connection and noises in
the reassembled network, the predictive model in this
study was still far more completed. We proposed that
our study on the off-target effects of torcetrapib based
on network pharmacology will provide beneficial insights
for further experimental validations.
Methods
Microarray data analysis
The microarray gene expression profiling associated with
torcetrapib was acquired from the National Center for
Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) data-
base under the accession number GDS3556 [50]. This
data set was derived from a study on H295 adrenal carcin-
oma cells treated with blank solvent, AngII and torcetra-
pib. Analysis of differently expression gene was performed
by Significance Analysis of Microarray (SAM) [51]. If the
fold change>1.2 and False Discovery Rate (FDR)<0.05,
gene expression was considered significantly different.) Docked complex of HGFR (PDB code 3UH6) and compound 03X in
best docking pose. Compound 03X and torcetrapib were in the stick
solid ribbon style in the line representation. C, H, O, N and F were
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To establish a comprehensive human signaling network,
we manually curated the cellular signaling molecules
which integrated diverse pathways resources including
BioCarta, literature-mined network, Cancer Cell Map
[13] and HPRD. An open source platform for complex
network analysis and visualization named Cytoscape was
freely utilized to assemble the drug-gene interaction net-
work [14]. Molecular inter-relations in the integrative
network were added using BisoGenet plugin from vari-
ous databases including BIND, HPRD, MINT, DPI, BIO-
GRID and INTACT [15].Functional enrichment analysis
Functional enrichment analysis was applied to identify
primary biological processes, which provided clues to
the underlying molecular mechanisms related to the ad-
verse effects of torcetrapib. Significant clustering of
genes was mined by MCODE algorithm [16]. All GRNs
modules were classified by DAVID functional annotation
tool [17,18] to perform GO analysis on the basis of
“GOTERM_BP_FAT”, whilst pathway enrichment ana-
lysis was clustered by ToppFun [19].Ligand preparation
Chemical structures of all ligands utilized in reverse
docking protocol were generated by CambridgeSoft
ChemOffice 2008. Ligands were prepared by adding
charges, hydrogen and applying force field in Discovery
Studio environment. Energy was also minimized with
ChARMm force field before performing docking. The
random conformations search of torcetrapib was con-
ducted utilizing a high temperature simulated annealing
dynamics scheme. Ligands were heated to 700 K in 2000
steps, followed by annealing to 300 K in 5000 steps. Ten
random conformations were generated and a final
minimization was introduced to each docking poses.Receptor preparation
The three dimensional structures of proteins were
obtained from PDB, which contains information about
experimentally-determined structures of proteins, nu-
cleic acids and complex assemblies. Drug targets were
downloaded with high resolution and without mutation
or missing residues around the active site. Ligands, oli-
gomeric chains, water molecules or solvent were spilt
from proteins. All proteins were remedied through the
“Prepare Protein” command in Discovery Studio proto-
cols, which added hydrogen, fixed the missing side
chains, corrected connectivity or bond orders and
adjusted residue protonation states to PH 7.0.Binding site analysis
For binding site identification, a ligand-based approach
was used for identifying the potential binding sites via
“Define and Edit Binding Site” tool in Discovery Studio.
Ligand-based similarity search method, a strategy utiliz-
ing compounds that are known to bind to the desired
targets to identify the targets of other compounds with
similar properties, is an indispensable technology that is
gaining increasing usage in drug discovery. In the
present study, search was performed on the global sur-
face of the protein by similarity and substructure search-
ing [52], and the automatic identification of binding
sphere was considered as highly significant.
Targets prediction
A reverse docking algorithm, the opposite of a “direct”
docking approach, was conducted by CDOCKER to hunt
for potential targets of torcetrapib based on the enriched
signaling pathways. CDOCKER, an implementation
protocol in Discovery Studio environment, is a grid-
based simulated annealing (several cycles) docking
method through CHARMm force field docking tool
[53]. Docking was performed using the default setting,
which can avoid a potential reduction in docking
accuracy.
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